Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells

INTRODUCTION: Despite multiple advances in the treatment of HER2+ breast cancers, resistance develops even to combinations of HER2 targeting agents. Inhibition of PI3K pathway signaling is critical for the efficacy of HER2 inhibitors. Activating mutations in PIK3CA can overlap with HER2 amplificatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Rexer, Brent N, Chanthaphaychith, Siprachanh, Dahlman, Kimberly Brown, Arteaga, Carlos L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978602/
https://www.ncbi.nlm.nih.gov/pubmed/24451154
http://dx.doi.org/10.1186/bcr3601

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978602/
https://www.ncbi.nlm.nih.gov/pubmed/24451154
http://dx.doi.org/10.1186/bcr3601

Ejemplares similares